Translational Medicine meetings & conferences

Society for Immunotherapy of Cancer 27th Annual Meeting

October 26-28, 2012 North Bethesda, Maryland

The SITC 27th Annual Meeting allows for scientific exchange of the most cutting-edge preclinical and clinical data on immunotherapies and biological therapy of cancer. The program included dynamic presentations, interactive panel discussions and scientific posters on the most timely topics in cancer immunotherapy as well as vital information on clinical trial design and regulatory issues to advance collaboration and translation of cancer immunotherapies.

SITC is ideally positioned to meet the identified needs of our attendees. SITC’s strength lies in its history of organizing successful scientific conferences that gather clinicians and scientists from around the globe to interact and discuss the most important issues in cancer immunotherapy. By addressing these needs, SITC advances effective, efficient research and interaction on promising cancer therapies with biological and immunological agents. Through its integrated programs, SITC promotes productive collaboration among scientists and with other organizations in the field. Ultimately this scientific exchange and collaborative environment will lead to better cancer patient outcomes with novel cancer immunotherapies.

The SITC 27th Annual Meeting program format and content is designed to address identified needs/practice gaps and promotes:

Exchange between basic and clinical researchers, thus improving the caliber of the science and promoting translation
Discussion on potential hurdles in cancer immunotherapy from the trial design and regulatory perspective
Integrated understanding of the state of cancer immunotherapy research in today’s environment, identification of potential funding opportunities, and mentoring of junior investigators
Discussion of novel therapies and applications based on the research presented
Interactions with industry to promote access to novel agents for clinical development

Intended Audience

The audience for this program is basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, postdoctoral fellows, and allied health professionals involved in cancer research.

Program Goals

Exchange information on the most recent advances in tumor immunology and cancer immunotherapy
Convey recent advances in biology and immunotherapy as they relate to specific cancers and various immunotherapy modalities, cell subsets, animal models, and aspects of negative regulation in the tumor microenvironment
Identify promising research opportunities, new techniques and clinical applications incorporating these advances
Establish dialogue between academia, industry and government on these advances

Expected Learner Outcomes

Upon completion of this program, the participants will be able to:

Summarize the most recent advances in tumor immunology and cancer immunotherapy
Integrate recent advances in cancer immunology and immunotherapy into basic, clinical and translational research
Incorporate new research and techniques into clinical applications for cancer immunotherapy
Establish and solidify collaborations among the various members of academia, industry, government and clinical practices to promote clinical evaluation of these advances in more efficient trials

Stem Cells Forum: Working Towards Clinical Application

Wednesday, 03 October 2012 09:00 - 17:00

London, United Kingdom

This event is discussion forum, focused on clinical applications of stem cell therapy. The aim is to offer participants a chance to explore aspects with the experts during round table and one-to one discussions.

Meeting Chair: Dr Glyn Stacey, UK Stem Cell Bank, Division of Cell Biology and Imaging.

Contact Details

Meeting Secretariat Email: astrid.englezou@euroscicon.com

General Enquires Email: enquiries@euroscicon.com

Markers in Cancer 2012

October 11-13, 2012 Holywood, Florida

Markers in Cancer 2012 (formerly known as the ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer) will stimulate discussion on the use of biomarkers as a tool for optimizing detection and treatment in oncology.

Designed for clinicians, pathologists, clinical and translational researchers, statisticians, radiologists, and others who specialize in molecular diagnostics, the meeting will present the latest advances in cancer markers to assess drug efficacy, improve prognostic and predictive evaluations and imaging, and enhance clinical trial development.

This year's Meeting will focus on practice-oriented translational research. Join us in Florida to review and explore the latest innovations in cancer markers.

2012 Breast Cancer Symposium

September 13-15 San Francisco, California

The evolved, enhanced program will combine didactic educational sessions with the presentation of abstracts, to illustrate and explain emerging clinical science.

European Society for Organ Transplantation-American Society of Transplantation Joint Meeting: Transformational Therapies and Diagnostics in Transplantation

Partnering to bring you the best transplantation science!

October 12-14, 2012 Nice, France

Special topics include:

• Optimizing Co-Stimulation Blockade
• Can Pharmacogenetics Lead to Individualized Immunosuppression?: Clinical Relevance of Pharmacogenetics of Donor and Recipient
• Current Pipeline in Biotech and Pharma
• Unfulfilled Targets in Transplantation
• Controversies in Transplantation: What is currently considered optimal therapy and why? Is chronic rejection inevitable?

For more information, visit the ESOT website.

Contact information

AST
Tina Squillante, AST Director of Meetings
Telephone: 001 856-642-4436
Fax: 001 856-439-9982
Email: tsquillante@ahint.com

ESOT
Annalisa Ponchia, ESOT Executive Officer
Telephone: 0039 049 3005796
Fax: 0039 049 2106306
Email: executive@esot.org

Chiara Parisotto, Courses & Meetings Coordinator
Telephone: 0039 049 3005796
Fax: 0039 049 2106306
Email: operations@esot.org

Current and Future Applications of Focused Ultrasound 2012

October 14-17, 2012 Washington DC

Organized by the Focused Ultrasound Surgery Foundation, the symposium will spotlight leading edge preclinical, translational and clinical research related to one of today’s most promising and innovative therapeutic technologies.

Targeted to scientists, clinicians and others interested in current and future applications of focused ultrasound, the conference will offer a multifaceted exploration of this emerging field and feature plenary sessions, panel discussions, poster presentations and technical exhibits.

Symposium topics include:

Brain

Breast tumors

Cardiovascular

Head and neck

Liver

Bone

Pancreas

Prostate

Uterine Fibroids
 

3rd AMA-IEEE Medical Technology Conference: Translational Engineering in Health & Medicine: the Intersection of the Lab, the Clinic and the Community

The American Medical Association (AMA) and the IEEE Engineering in Medicine and Biology (EMB) Society are pleased to announce the 3rd AMA-IEEE Medical Technology Conference: Translational Engineering in Health & Medicine: the intersection of the lab, the clinic and the community in Houston, TX, on 7th-9th November 2012 at the Methodist Hospital Research Institute in the Texas Medical Center.

This conference is devoted to the exploration of the intersection of engineering, medicine, and health. Emphasis will be placed on novel innovations that have a foreseeable impact on human health and disease. Specific areas of interest include Imaging; Nano Medicine; Data Mining and the Use of Large Datasets; Remote Sensing; Networks & Communication; Applied Metabolomics; Aerospace and Harsh Environments; and Global Health.

We invite participation by physicians, nurses and other healthcare professionals, engineers, innovators, entrepreneurs, industrial leaders, government agencies and policy makers. The conference will be inaugurated by a keynote lecture and evening reception on Wednesday, 7th November. The following two days will feature plenary, break-out sessions and poster presentations focusing on Translational Engineering in Health & Medicine.

The Lung – a Pivotal Player in Systemic Inflammatory Disorders

June 11-12, 2012 Solna, Sweden

As representatives of the Executive Committee and Advisory Board of this symposium we are happy to invite you to participate in this unique symposium on systemic inflammatory disorders. It is arranged by representatives from both clinic and research, and by specialists in pulmonary medicine, rheumatology and neurology enabling fruitful information and discussions on general topics as well as on specific issues. The high quality of the meeting is reflected by the use of the trade mark “Karolinska Institutet Conferences”, and internationally well recognized speakers further guarantee that interesting data will be presented.

The symposium is arranged as a result of recent data on how smoking and genetic factors have a great impact not only on the lungs but also on other organs affected in systemic inflammatory disorders. These findings call for more intensive collaborations in the future between clinicians representing different specialties’ and for research of truly translational character.

Introductory speeches will be given to inform about common clinical findings which may reflect lung involvement in systemic disorders, and how they can be established. Smoking and co-morbidity in systemic inflammatory disorders will be discussed, and the role of interstitial lung involvement in myositis, rheumatoid arthritis and multiple sclerosis will be elucidated. Can smoking related changes in the lung trigger joint inflammation, or increase the risk of getting myositis or MS? Another topic is the genetic and possible etiological background in sarcoidosis.

Up-to-date treatment of interstitial lung involvement, pros and cons, and the effects of smoking on treatment will be debated followed by an overview of failures and successes of smoking cessation programs.

You will also at a poster-viewing session be given the opportunity to informally discuss your own abstract. Can you really afford not to participate?

Congrex Sweden AB
Attn: The Lung

Telephone/fax
T: +46 8 459 66 00
F: +46 8 661 91 25

General requests
thelung2012@congrex.com
Registration and hotel matters
thelung2012.registration@congrex.com

Temporomandibular Joint Disorder Bioengineering Conference

Thursday September 20 through Saturday September 22, 2012 Pittsburgh, Pennsylvania.

The meeting will provide a unique opportunity for bioengineers, clinicians and scientists to discuss the challenges presented by temporomandibular joint disorders, and to devise strategies to address those challenges.

Objectives

The overall meeting objective is to organize a scientific conference exclusively dedicated to the TMJ, and to advance the field of TMJ research and strengthen the continuity among clinicians, scientists and bioengineers in this pursuit.

This overall objective will be addressed by the following specific objectives:

Provide recommendations to the NIDCR TMJD Program on novel scientific approaches and critical research topics that will advance the field.
Establish a benchmark for current treatments and scientific knowledge.
Bring outside perspective from experts in areas pertinent to TMJ research.

You Should Attend If…

You are not currently in TMJ research, but are looking for new and relatively unexplored funding areas where you can apply your research strengths.
You are currently a TMJ researcher and want to keep up with the latest advances in the field.
You are looking for collaborators in TMJ research.
You are a bioengineer, and want to know the practical needs of surgeons and patients.
You are a clinician, and want to understand the capabilities of the engineering community.

For more information on the conference, contact

Alejandro J. Almarza, Ph.D.
Conference Chair
566 Salk Hall
3501 Terrace Street, 15261
(412) 648-15243
aja19@pitt.edu
University of Pittsburgh
Pittsburgh, PA

13th Annual Bioinformatics Open Source Conference (BOSC 2012)

The 13th Annual Bioinformatics Open Source Conference (BOSC 2012) will take place July 13-14, 2012, in Long Beach, CA, right before ISMB 2012.

The Bioinformatics Open Source Conference (BOSC) is sponsored by the Open Bioinformatics Foundation (O|B|F), a non-profit group dedicated to promoting the practice and philosophy of Open Source software development within the biological research community.

Open Source software has flourished in the bioinformatics community for well over a decade. When the first BOSC (Bioinformatics Open Source Conference) was held in 2000, there were already a number of popular open source bioinformatics packages, and the number and range of these projects has increased dramatically since then. Many open source bioinformatics packages are widely used by the research community across a wide variety of applications. Open source bioinformatics software has facilitated rapid innovation, dissemination, and wide adoption of new computational methods, reusable software components, and standards.

BOSC brings together bioinformatics open source developers from all over the world so they can forge connections each other (both within and across projects), increase the visibility of their work, and collaborate to build shared resources. Participants can work together to create use cases, prototype working code, or run hands-on tutorials in new software packages and emerging technologies. For those who are bioinformatics software users rather than developers, BOSC introduces or updates them on a wide array of projects that they might find useful.

Sessions

Cloud and Parallel Computing -- This session will cover cloud-based approaches to improving software and data accessibility. The emergence of cloud computing has made highly scalable cluster computing available to computational biologists. Services such as Amazon's Elastic Compute Cloud combined with publicly available datasets promise to lower the overhead to participate in large scale data analyses. Talks will focus on how the community can build up resources, datasets, and workflows for making the best use of cloud infrastructure. We will also include talks on data-parallel approaches to analyzing massive data sets, such as those resulting from next-generation sequencing and mass spec proteomics, and reports on the parallelization of bioinformatics algorithms in general.

Linked Data -- Linked Data is an emerging set of conventions on using basic Semantic Web standards (HTTP URIs and RDF in particular) to expose, share, and connect data, information, and knowledge online. Linked Data principles are increasingly being embraced by bioinformatics resources. For example, UniProt is now being made fully available in RDF , and collaborative initiatives such as Bio2RDF aim to expose many commonly used database resources to data integration through RDF and its query language, SPARQL. This session is devoted to reports on software that works with such new data stores, or aids in their development, including technologies for interoperable web services, and tools for ontology building or maintenance.

Genome-scale Data Management -- This session will focus on processes and technologies that support the creating, managing and reporting of genomic data. This session is appropriate for discussion of systems that involve components such as (but not limited to) Ensembl and GMOD/Chado data stores, Taverna and Galaxy analysis workflows, and BioMart and InterMine warehouses.

Data Visualization and Imaging -- This session will address visualization techniques and tools that provide insight into large and highly complex biomedical data sets , as well as biological image processing, analysis and data management. Talks that address the development of frameworks and communities are particularly welcome.

Translational Bioinformatics -- This session will explore applications of biological and medical informatics to the development of personalized healthcare, therapies, and a better understanding of human health and disease. Topics include the analysis of human microarray and other 'omics data, bioinformatics methodologies for clinical research, and tools for discovering clinically useful associations in human databases.

Bioinformatics Open Source Project Updates -- This session will feature short talks from ongoing projects describing their recent progress. Abstracts will be solicited from open source projects affiliated with the O|B|F (see http://www.open-bio.org/wiki/Projects), including the Bio projects, DAS, BioMOBY, EMBOSS, and GMOD, but any other open-source project will be equally eligible to submit presentations for this session.

Panel: Interfacing with Industry -- Companies are more and more seeing the benefits of working with open source code and making their own code open; meanwhile, academics frequently partner with companies on their research projects. We encourage submissions from companies that work with open source software, as well as developers from non-commercial organizations who collaborate with companies. We anticipate a broadly useful conversation about the benefits and pitfalls of academic/commercial interaction.